UK markets open in 17 minutes
  • NIKKEI 225

    22,977.13
    -354.81 (-1.52%)
     
  • HANG SENG

    24,038.13
    -548.47 (-2.23%)
     
  • CRUDE OIL

    35.87
    -0.30 (-0.83%)
     
  • GOLD FUTURES

    1,870.90
    +2.90 (+0.16%)
     
  • DOW

    26,659.11
    +139.16 (+0.52%)
     
  • BTC-GBP

    10,243.07
    -186.96 (-1.79%)
     
  • CMC Crypto 200

    259.36
    +16.69 (+6.88%)
     
  • ^IXIC

    11,185.59
    +180.72 (+1.64%)
     
  • ^FTAS

    3,152.13
    -3.12 (-0.10%)
     

Global Uterine Cancer Therapeutics & Diagnostics Industry

ReportLinker
·25-min read

Global Uterine Cancer Therapeutics and Diagnostics Market to Reach US$27. 7 Billion by the Year 2027. Amid the COVID-19 crisis, the global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$19.

New York, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Uterine Cancer Therapeutics & Diagnostics Industry" - https://www.reportlinker.com/p05960383/?utm_source=GNW
5 Billion in the year 2020, is projected to reach a revised size of US$27.7 Billion by 2027, growing at a CAGR of 5.1% over the period 2020-2027.Uterine Sarcomas, one of the segments analyzed in the report, is projected to grow at a 3.9% CAGR to reach US$9.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Endometrial Carcinomas segment is readjusted to a revised 5.8% CAGR for the next 7-year period. This segment currently accounts for a 62.4% share of the global Uterine Cancer Therapeutics and Diagnostics market.

The U.S. Accounts for Over 28.8% of Global Market Size in 2020, While China is Forecast to Grow at a 8.5% CAGR for the Period of 2020-2027

The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.6 Billion in the year 2020. The country currently accounts for a 28.79% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$5.1 Billion in the year 2027 trailing a CAGR of 8.6% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR while Rest of European market (as defined in the study) will reach US$5.1 Billion by the year 2027.We bring years of research experience to this 9th edition of our report. The 388-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Abbott Laboratories, Inc.

  • ARIAD Pharmaceuticals, Inc.

  • Becton, Dickinson and Company

  • F. Hoffmann-La Roche AG

  • Merck & Co., Inc.

  • Novartis AG

  • Sanofi SA

  • Siemens Healthineers




Read the full report: https://www.reportlinker.com/p05960383/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Uterine Cancer Therapeutics & Diagnostics Competitor Market
Share Scenario Worldwide (in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Billion for Years 2018 through 2027

Table 2: World Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 3: World 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2018 & 2027

Table 4: World Current & Future Analysis for Uterine Sarcomas
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 5: World Historic Review for Uterine Sarcomas by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 6: World 15-Year Perspective for Uterine Sarcomas by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 7: World Current & Future Analysis for Endometrial
Carcinomas by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Billion
for Years 2018 through 2027

Table 8: World Historic Review for Endometrial Carcinomas by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 9: World 15-Year Perspective for Endometrial Carcinomas
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 10: World Current & Future Analysis for Surgery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 11: World Historic Review for Surgery by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 12: World 15-Year Perspective for Surgery by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2018 & 2027

Table 13: World Current & Future Analysis for Immunotherapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 14: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 15: World 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 16: World Current & Future Analysis for Radiation Therapy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 17: World Historic Review for Radiation Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 18: World 15-Year Perspective for Radiation Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 19: World Current & Future Analysis for Chemotherapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 20: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 21: World 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 22: World Current & Future Analysis for Follow-Up
Treatment by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Billion
for Years 2018 through 2027

Table 23: World Historic Review for Follow-Up Treatment by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 24: World 15-Year Perspective for Follow-Up Treatment by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 25: World Current & Future Analysis for Biopsy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 26: World Historic Review for Biopsy by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 27: World 15-Year Perspective for Biopsy by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2018 & 2027

Table 28: World Current & Future Analysis for Pelvic Ultrasound
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 29: World Historic Review for Pelvic Ultrasound by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 30: World 15-Year Perspective for Pelvic Ultrasound by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 31: World Current & Future Analysis for Hysteroscopy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 32: World Historic Review for Hysteroscopy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 33: World 15-Year Perspective for Hysteroscopy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 34: World Current & Future Analysis for Dilation and
Curettage by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Billion
for Years 2018 through 2027

Table 35: World Historic Review for Dilation and Curettage by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 36: World 15-Year Perspective for Dilation and Curettage
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2018 & 2027

Table 37: World Current & Future Analysis for CT scan by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 38: World Historic Review for CT scan by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Billion for Years 2012 through 2017

Table 39: World 15-Year Perspective for CT scan by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Uterine Cancer Therapeutics & Diagnostics Market Share
(in %) by Company: 2018 & 2027
Market Analytics
Table 40: USA Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas - Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 41: USA Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial
Carcinomas Markets - Independent Analysis of Annual Sales in
US$ Billion for Years 2012 through 2017

Table 42: USA 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Percentage
Breakdown of Value Sales for Uterine Sarcomas and Endometrial
Carcinomas for the Years 2012, 2018 & 2027

Table 43: USA Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment - Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 44: USA Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 45: USA 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Percentage
Breakdown of Value Sales for Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment for the Years
2012, 2018 & 2027

Table 46: USA Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 47: USA Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 48: USA 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Percentage
Breakdown of Value Sales for Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan for the Years
2012, 2018 & 2027

CANADA
Table 49: Canada Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas - Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 50: Canada Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 51: Canada 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Percentage
Breakdown of Value Sales for Uterine Sarcomas and Endometrial
Carcinomas for the Years 2012, 2018 & 2027

Table 52: Canada Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment - Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 53: Canada Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment Markets - Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 54: Canada 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Percentage
Breakdown of Value Sales for Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment for the Years
2012, 2018 & 2027

Table 55: Canada Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 56: Canada Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan
Markets - Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 57: Canada 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Percentage
Breakdown of Value Sales for Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan for the Years
2012, 2018 & 2027

JAPAN
Table 58: Japan Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas - Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 59: Japan Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial
Carcinomas Markets - Independent Analysis of Annual Sales in
US$ Billion for Years 2012 through 2017

Table 60: Japan 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Percentage
Breakdown of Value Sales for Uterine Sarcomas and Endometrial
Carcinomas for the Years 2012, 2018 & 2027

Table 61: Japan Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment - Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 62: Japan Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Therapeutics - Surgery, Immunotherapy,
Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 63: Japan 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Percentage
Breakdown of Value Sales for Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment for the Years
2012, 2018 & 2027

Table 64: Japan Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 65: Japan Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 66: Japan 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Percentage
Breakdown of Value Sales for Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan for the Years
2012, 2018 & 2027

CHINA
Table 67: China Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas - Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 68: China Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial
Carcinomas Markets - Independent Analysis of Annual Sales in
US$ Billion for Years 2012 through 2017

Table 69: China 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Percentage
Breakdown of Value Sales for Uterine Sarcomas and Endometrial
Carcinomas for the Years 2012, 2018 & 2027

Table 70: China Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment - Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 71: China Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Therapeutics - Surgery, Immunotherapy,
Radiation Therapy, Chemotherapy and Follow-Up Treatment Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 72: China 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Percentage
Breakdown of Value Sales for Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment for the Years
2012, 2018 & 2027

Table 73: China Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 74: China Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 75: China 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Percentage
Breakdown of Value Sales for Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan for the Years
2012, 2018 & 2027

EUROPE
Market Facts & Figures
European Uterine Cancer Therapeutics & Diagnostics Market:
Competitor Market Share Scenario (in %) for 2018 & 2027
Market Analytics
Table 76: Europe Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2018 through 2027

Table 77: Europe Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 78: Europe 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2012, 2018 & 2027

Table 79: Europe Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas - Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 80: Europe Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 81: Europe 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Percentage
Breakdown of Value Sales for Uterine Sarcomas and Endometrial
Carcinomas for the Years 2012, 2018 & 2027

Table 82: Europe Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment - Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 83: Europe Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment Markets - Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 84: Europe 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Percentage
Breakdown of Value Sales for Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment for the Years
2012, 2018 & 2027

Table 85: Europe Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 86: Europe Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan
Markets - Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 87: Europe 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Percentage
Breakdown of Value Sales for Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan for the Years
2012, 2018 & 2027

FRANCE
Table 88: France Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas - Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 89: France Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 90: France 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Percentage
Breakdown of Value Sales for Uterine Sarcomas and Endometrial
Carcinomas for the Years 2012, 2018 & 2027

Table 91: France Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment - Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 92: France Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment Markets - Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 93: France 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Percentage
Breakdown of Value Sales for Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment for the Years
2012, 2018 & 2027

Table 94: France Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 95: France Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan
Markets - Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 96: France 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Percentage
Breakdown of Value Sales for Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan for the Years
2012, 2018 & 2027

GERMANY
Table 97: Germany Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas - Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 98: Germany Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 99: Germany 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Percentage
Breakdown of Value Sales for Uterine Sarcomas and Endometrial
Carcinomas for the Years 2012, 2018 & 2027

Table 100: Germany Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment - Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 101: Germany Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment Markets - Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 102: Germany 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Percentage
Breakdown of Value Sales for Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment for the Years
2012, 2018 & 2027

Table 103: Germany Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 104: Germany Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan
Markets - Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 105: Germany 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Percentage
Breakdown of Value Sales for Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan for the Years
2012, 2018 & 2027

ITALY
Table 106: Italy Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas - Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 107: Italy Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas Markets - Independent Analysis of
Annual Sales in US$ Billion for Years 2012 through 2017

Table 108: Italy 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Percentage
Breakdown of Value Sales for Uterine Sarcomas and Endometrial
Carcinomas for the Years 2012, 2018 & 2027

Table 109: Italy Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment - Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 110: Italy Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment Markets - Independent Analysis of Annual Sales in US$
Billion for Years 2012 through 2017

Table 111: Italy 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Percentage
Breakdown of Value Sales for Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment for the Years
2012, 2018 & 2027

Table 112: Italy Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 113: Italy Historic Review for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan
Markets - Independent Analysis of Annual Sales in US$ Billion
for Years 2012 through 2017

Table 114: Italy 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Percentage
Breakdown of Value Sales for Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan for the Years
2012, 2018 & 2027

UNITED KINGDOM
Table 115: UK Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Uterine Sarcomas
and Endometrial Carcinomas - Independent Analysis of Annual
Sales in US$ Billion for the Years 2018 through 2027

Table 116: UK Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Cancer Type - Uterine Sarcomas and Endometrial
Carcinomas Markets - Independent Analysis of Annual Sales in
US$ Billion for Years 2012 through 2017

Table 117: UK 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Cancer Type - Percentage
Breakdown of Value Sales for Uterine Sarcomas and Endometrial
Carcinomas for the Years 2012, 2018 & 2027

Table 118: UK Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Surgery,
Immunotherapy, Radiation Therapy, Chemotherapy and Follow-Up
Treatment - Independent Analysis of Annual Sales in US$ Billion
for the Years 2018 through 2027

Table 119: UK Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Therapeutics - Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 120: UK 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Therapeutics - Percentage
Breakdown of Value Sales for Surgery, Immunotherapy, Radiation
Therapy, Chemotherapy and Follow-Up Treatment for the Years
2012, 2018 & 2027

Table 121: UK Current & Future Analysis for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Biopsy, Pelvic
Ultrasound, Hysteroscopy, Dilation and Curettage and CT scan -
Independent Analysis of Annual Sales in US$ Billion for the
Years 2018 through 2027

Table 122: UK Historic Review for Uterine Cancer Therapeutics &
Diagnostics by Diagnostics - Biopsy, Pelvic Ultrasound,
Hysteroscopy, Dilation and Curettage and CT scan Markets -
Independent Analysis of Annual Sales in US$ Billion for Years
2012 through 2017

Table 123: UK 15-Year Perspective for Uterine Cancer
Therapeutics & Diagnostics by Diagnostics - Percentage
Breakdown of Value Sales for Biopsy, Pelvic Ultrasound,

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05960383/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001